Thiard News@F4F

@newsen.bsky.social

10 months ago

Spyre Therapeutics Reports Promising Phase 1 Results for Revolutionary TL1A Antibody Therapies Spyre Therapeutics has announced encouraging interim Phase 1 results for its innovative TL1A antibody programs, SPY002 and SPY072, moving towards Phase 2 trials that could drive significant market impact.

Spyre Therapeutics Reports Promising Phase 1 Results for Revolutionary TL1A Antibody Therapies #United_States #Spyre_Therapeutics #Waltham #SPY002 #TL1A_Antibodies

Thiard News@F4F

@newsen.bsky.social

10 months ago

Spyre Therapeutics Conference Call to Share Interim Trial Results for SPY002 Program Spyre Therapeutics will host a conference call on June 17, 2025, to report interim results from its Phase 1 trials for the SPY002 program, a new treatment for IBD.

Spyre Therapeutics Conference Call to Share Interim Trial Results for SPY002 Program #United_States #Spyre_Therapeutics #Waltham #IBD #SPY002

Thiard News@F4F

@newsen.bsky.social

10 months ago

Spyre Therapeutics Offers Stock Options Under Inducement Awards to Employees Spyre Therapeutics, a biotech firm, has granted stock options to three new employees as part of their equity inducement strategy, enhancing employee retention.

Spyre Therapeutics Offers Stock Options Under Inducement Awards to Employees #United_States #Spyre_Therapeutics #IBD_treatment #Waltham #biotech_company

Thiard News@F4F

@newsen.bsky.social

10 months ago

Spyre Therapeutics to Engage in Key Investor Conferences for Growth Spyre Therapeutics, Inc. is set to present at major investor conferences, focusing on innovative treatments for inflammatory bowel disease and other immune disorders.

Spyre Therapeutics to Engage in Key Investor Conferences for Growth #USA #Spyre_Therapeutics #Waltham #IBD #antibody_engineering

Thiard News@F4F

@newsen.bsky.social

11 months ago

Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates Spyre Therapeutics shares encouraging results from Q1 2025, highlighting progress in clinical trials for IBD and RA while strengthening its financial position.

Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates #USA #Spyre_Therapeutics #Waltham #IBD_Research #RA_Treatment

Thiard News@F4F

@newsen.bsky.social

11 months ago

Spyre Therapeutics to Present SPY001 Phase 1 Trial Data at DDW 2025 Spyre Therapeutics is set to unveil promising data for SPY001, a groundbreaking treatment for Inflammatory Bowel Disease, during Digestive Disease Week 2025.

Spyre Therapeutics to Present SPY001 Phase 1 Trial Data at DDW 2025 #United_States #San_Diego #Inflammatory_Bowel_Disease #Spyre_Therapeutics #SPY001

Thiard News@F4F

@newsen.bsky.social

11 months ago

Spyre Therapeutics Grants Inducement Awards to Enhance Recruitment Success Spyre Therapeutics has recently announced the issuance of stock options as inducement awards to enhance its recruitment, targeting key positions in drug development.

Spyre Therapeutics Grants Inducement Awards to Enhance Recruitment Success #United_States #stock_options #Spyre_Therapeutics #Waltham #Inducement_Awards

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Grants Stock Options to Boost Team Recruitment Spyre Therapeutics has awarded stock options to five employees under their 2018 Equity Inducement Plan, enhancing recruitment efforts.

Spyre Therapeutics Grants Stock Options to Boost Team Recruitment #USA #stock_options #Spyre_Therapeutics #Waltham #IBD

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Doses First Participant in SPY003 Phase 1 Clinical Trial for IBD Treatment Spyre Therapeutics has commenced its Phase 1 trial for SPY003, a promising IL-23 antibody. This innovation could enhance treatment options for inflammatory bowel disease.

Spyre Therapeutics Doses First Participant in SPY003 Phase 1 Clinical Trial for IBD Treatment #United_States #Spyre_Therapeutics #Waltham #SPY003 #IL-23_Antibody

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Grants Equity Inducement Awards to Employees Enhancing Job Attraction Spyre Therapeutics has announced the approval of stock options for employees as part of an equity inducement plan, enhancing employee attraction and retention.

Spyre Therapeutics Grants Equity Inducement Awards to Employees Enhancing Job Attraction #USA #Spyre_Therapeutics #Waltham #SYRE #IBD

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Reports Promising Results and Financial Update for 2024 Spyre Therapeutics unveiled positive trial results and financial growth for 2024, reflecting their commitment to innovative therapies for inflammatory diseases.

Spyre Therapeutics Reports Promising Results and Financial Update for 2024 #USA #Spyre_Therapeutics #Waltham #SPY001 #SPY002

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics to Showcase Advances at March Investor Conferences Spyre Therapeutics, specializing in innovative treatments for immune-mediated diseases, will participate in two major investor conferences this March.

Spyre Therapeutics to Showcase Advances at March Investor Conferences #USA #Spyre_Therapeutics #biotechnology #Waltham #IBD

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Showcases Promising Findings at ECCO 2025 on Innovative IBD Treatments Spyre Therapeutics presents pivotal research at the ECCO conference, demonstrating enhanced efficacy for IBD therapies combining two antibody targets. Find out more!

Spyre Therapeutics Showcases Promising Findings at ECCO 2025 on Innovative IBD Treatments #Germany #Berlin #Spyre_Therapeutics #IBD_Research #ECCO_2025

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Incentive Awards Spyre Therapeutics announces the approval of stock options to three non-executive employees under its 2018 Equity Inducement Plan, enhancing recruitment efforts.

Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Incentive Awards #United_States #stock_options #Spyre_Therapeutics #Waltham #Biotech_Industry

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Investigates Potential Securities Violations by Spyre Therapeutics, Inc. - Important Insights for Investors The Pomerantz Law Firm is probing into claims made on behalf of investors of Spyre Therapeutics, Inc. amidst allegations of securities fraud and reporting inaccuracies.

Pomerantz Law Firm Investigates Potential Securities Violations by Spyre Therapeutics, Inc. - Important Insights for Investors #United_States #New_York #Spyre_Therapeutics #Pomerantz_LLP #SYRE

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Investigates Next Steps for Investors of Spyre Therapeutics Amid Fraud Allegations Pomerantz LLP is conducting an investigation into Spyre Therapeutics, addressing potential securities fraud following critical financial misstatements.

Pomerantz Law Firm Investigates Next Steps for Investors of Spyre Therapeutics Amid Fraud Allegations #USA #New_York #Spyre_Therapeutics #Pomerantz_LLP #Investor_Claims

Thiard News@F4F

@newsen.bsky.social

1 year ago

New Developments in Spyre Therapeutics Shareholder Investigation Led by Pomerantz Law Firm Pomerantz Law Firm is probing potential securities fraud involving Spyre Therapeutics, raising significant concerns for investors amidst recent stock drops.

New Developments in Spyre Therapeutics Shareholder Investigation Led by Pomerantz Law Firm #United_States #New_York #Securities_Fraud #Spyre_Therapeutics #Pomerantz_Law_Firm

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Outlines Ambitious Plans and Goals for 2025 with Strong Pipeline Additions Spyre Therapeutics sets exciting priorities for 2025, including new treatments for IBD and rheumatoid arthritis, backed by solid financials.

Spyre Therapeutics Outlines Ambitious Plans and Goals for 2025 with Strong Pipeline Additions #USA #Spyre_Therapeutics #Waltham #IBD #rheumatoid_arthritis

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Probes Claims Related to Spyre Therapeutics Investors Pomerantz LLP is investigating potential securities fraud claims against Spyre Therapeutics, Inc., urging affected investors to reach out for support.

Pomerantz Law Firm Probes Claims Related to Spyre Therapeutics Investors #USA #New_York #Spyre_Therapeutics #Pomerantz_LLP #SYRE

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Probes Alleged Securities Fraud at Spyre Therapeutics: What Investors Need to Know Pomerantz Law Firm is investigating possible securities fraud by Spyre Therapeutics. The investigation follows troubling financial disclosures affecting shareholder value.

Pomerantz Law Firm Probes Alleged Securities Fraud at Spyre Therapeutics: What Investors Need to Know #United_States #New_York #Spyre_Therapeutics #Pomerantz_LLP #SEC_Investigation

Thiard News@F4F

@newsen.bsky.social

1 year ago

Legal Investigation Launched for Spyre Therapeutics Investors Following Financial Irregularities Pomerantz LLP is investigating potential securities fraud involving Spyre Therapeutics. Investors may seek legal recourse as details unfold about financial irregularities.

Legal Investigation Launched for Spyre Therapeutics Investors Following Financial Irregularities #USA #New_York #Spyre_Therapeutics #Pomerantz_LLP #SYRE

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Joins the Prestigious Nasdaq Biotechnology Index Spyre Therapeutics, Inc. has officially been added to the Nasdaq Biotechnology Index, enhancing its visibility and growth potential in the biotech sector.

Spyre Therapeutics Joins the Prestigious Nasdaq Biotechnology Index #United_States #Spyre_Therapeutics #Waltham #IBD #Nasdaq_Biotechnology

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Investigates Shareholder Claims Against Spyre Therapeutics Amid Financial Reporting Issues Pomerantz LLP is probing allegations of securities fraud by Spyre Therapeutics, following troubling financial disclosures that alarmed investors.

Pomerantz Law Firm Investigates Shareholder Claims Against Spyre Therapeutics Amid Financial Reporting Issues #USA #New_York #Spyre_Therapeutics #Pomerantz_LLP #SYRE

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Unveils Inducement Awards to Enhance Talent Acquisition Strategy Spyre Therapeutics has approved stock options as inducement awards for new hires to enhance its talent acquisition strategy in biotechnology.

Spyre Therapeutics Unveils Inducement Awards to Enhance Talent Acquisition Strategy #USA #stock_options #Spyre_Therapeutics #Waltham #IBD_Treatments

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Enters Phase 1 Trials with Innovative Anti-TL1A Antibodies Spyre Therapeutics has begun Phase 1 trials for its novel anti-TL1A antibodies, targeting enhanced treatment for inflammatory bowel diseases and promising greater efficacy and convenience.

Spyre Therapeutics Enters Phase 1 Trials with Innovative Anti-TL1A Antibodies #USA #Spyre_Therapeutics #Waltham #Anti-TL1A_Antibodies #IBD_Treatments

Thiard News@F4F

@newsen.bsky.social

1 year ago

Investigation Launched by Pomerantz Law Firm for Spyre Therapeutics Shareholders over Alleged Financial Misconduct Pomerantz Law Firm has initiated an investigation regarding claims from Spyre Therapeutics investors who experienced potential securities fraud. The ongoing inquiry focuses on previous financial statements and governance issues.

Investigation Launched by Pomerantz Law Firm for Spyre Therapeutics Shareholders over Alleged Financial Misconduct #USA #New_York #Spyre_Therapeutics #Pomerantz_Law_Firm #SEC_Investigation

Thiard News@F4F

@newsen.bsky.social

1 year ago

Spyre Therapeutics Set to Shine at the 7th Annual Evercore ISI HealthCONx Conference Spyre Therapeutics announces its participation in the 7th Annual Evercore ISI HealthCONx Conference, showcasing its innovative approaches in IBD treatment.

Spyre Therapeutics Set to Shine at the 7th Annual Evercore ISI HealthCONx Conference #United_States #Spyre_Therapeutics #IBD_treatment #biotechnology #Waltham